Clinical Translational Sciences, The University of Arizona Health Sciences, Tucson, Arizona, USA.
Epidemiology and Biostatistics, The University of Arizona Mel and Enid Zuckerman College of Public Health, Tucson, Arizona, USA.
BMJ Open. 2021 May 25;11(5):e046290. doi: 10.1136/bmjopen-2020-046290.
Owing to their propensity for being associated with infections, biofilms have become a focus in infectious disease research. There is evidence suggesting that statins, which are commonly used for prevention of cardiovascular disease, may prevent biofilm-associated infections, but this association has not been well-understood.
This systematic review protocol will include six database searches from their inception to 20 August 2020. A medical librarian will conduct the searches in PubMed, EMBASE, Web of Science, CINAHL, LILACS and CENTRAL, without any limits. Bibliographies of selected articles, previously published reviews and high-yield journals that publish on statins and/or biofilms will be searched to identify additional articles. The screening and data extraction will be conducted by two independent reviewers using DistillerSR. All included papers will also be evaluated for quality using Cochrane Risk of Bias Assessment tool, and we will examine for publication bias. If there are two or more studies with quantitative estimates that can be combined, we will conduct a meta-analysis after assessing for heterogeneity. We will report all findings according to the Preferred Reporting Items for Systematic reviews and Analyses-P framework.
There are conflicting results on the effect of statins on biofilm-associated infections. The rise of antibiotic resistance in medical settings warrants a deeper understanding of this association, especially if statins can be used as a novel antibiotic. The findings of this review will assess the association between statin use and biofilm-associated infection to inform future medical practice. No formal ethical review is required for this protocol. All findings will be published in a peer-reviewed journal.
CRD42020193985.
由于生物膜易于与感染相关，因此它们已成为传染病研究的重点。有证据表明，常用于预防心血管疾病的他汀类药物可能预防生物膜相关感染，但这种关联尚未得到很好的理解。
本系统评价方案将包括从创建到 2020 年 8 月 20 日的 6 个数据库搜索。医学图书馆员将在 PubMed、EMBASE、Web of Science、CINAHL、LILACS 和 CENTRAL 中进行搜索，不设置任何限制。将搜索选定文章的参考文献、以前发表的综述和发表他汀类药物和/或生物膜的高影响力期刊，以确定其他文章。筛选和数据提取将由两名独立评审员使用 DistillerSR 进行。所有纳入的论文还将使用 Cochrane 偏倚风险评估工具进行质量评估，并检查发表偏倚。如果有两项或更多具有可合并的定量估计值的研究，我们将在评估异质性后进行荟萃分析。我们将根据系统评价和分析优先报告项目（PRISMA）框架报告所有发现。
他汀类药物对生物膜相关感染的影响存在相互矛盾的结果。医疗环境中抗生素耐药性的上升需要更深入地了解这种关联，特别是如果他汀类药物可以用作新型抗生素。本综述的结果将评估他汀类药物使用与生物膜相关感染之间的关联，以为未来的医疗实践提供信息。本方案不需要进行正式的伦理审查。所有发现都将在同行评议的期刊上发表。
PROSPERO 注册号：CRD42020193985。
